You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Commercialization Readiness for Nerve Tape: a nerve repair coaptation aid

    SBC: BIOCIRCUIT TECHNOLOGIES INC            Topic: NINDS

    Project Summary This SBIR Commercialization Readiness Pilot project will prepare and achieve the commercial launch of Bio- Circuit Technologies’ Nerve Tape® device for sutureless nerve repair. Nerve injuries are common and result in paralysis, sensory loss, and chronic pain. In current repair techniques, the ends of a cut nerve are microsutured back together under high magnification by a specia ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Home Monitoring of Metabolic Disorders

    SBC: SEQUITUR HEALTH CORP            Topic: NICHD

    PROJECT SUMMARY This proposal is submitted in direct response to NOT-HD-22-009 Notice of Special Interest (NOSI): Innovative Technologies to Improve Assessments, Interventions, and Outcomes for Individuals with Intellectual and Developmental Disabilities [IDD] (R43/R44). Persons of all ages with certain metabolic disorders are at-risk for metabolic crises when a certain metabolite accumulates, whi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke

    SBC: NUVOX PHARMA, L.L.C.            Topic: NINDS

    ABSTRACT / PROJECT SUMMARY Stroke affects more than 795,000 patients per year in the US and kills approximately 40,000. Long-term medical care expense for stroke in the US, costs over $34B per year. Large vessel occlusion (LVO) stroke accounts for almost 40% of ischemic strokes but causes 95% of mortality and 62% of long-term dependence. Mechanical thrombectomy (MT), or a combination of MT and tPA ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Spinal Reflex Conditioning System for Enhancing Motor Function Recovery After Incomplete Spinal Cord Injury

    SBC: BIOCIRCUIT TECHNOLOGIES INC            Topic: 999

    Project Summary Spinal Cord Injury (SCI) affects ~300,000 people in the US, with 11,000 new cases/year. After SCI, spinal reflex function becomes abnormal, contributing to motor impairments and spasticity that affects 65-78% of people with SCI. Thus, restoring the function of spinal reflex pathways is a major therapeutic goal. Current therapies are only moderately successful; motor function often ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Thermally Modulated Solid-State Batteries for Ultra-Safe Fast-Charging Electric Vehicles

    SBC: Ampcera Inc.            Topic: 1

    Heatable solid-state batteries (SSBs) have the potential to enable high energy density and ultra-safe fast charging in electric vehicles (EVs) during cold weather overcoming many of the consumer acceptance barriers hindering widespread adoption. With proper material and system optimization, they are expected to reach desired charging rates of 4C or higher with 80% capacity retention at ambient tem ...

    SBIR Phase I 2023 Department of EnergyARPA-E
  7. Thermally Modulated Solid-State Batteries for Ultra-Safe Fast-Charging Electric Vehicles

    SBC: Ampcera Inc.            Topic: 1

    Heatable solid-state batteries (SSBs) have the potential to enable high energy density and ultra-safe fast charging in electric vehicles (EVs) during cold weather overcoming many of the consumer acceptance barriers hindering widespread adoption. With proper material and system optimization, they are expected to reach desired charging rates of 4C or higher with 80% capacity retention at ambient tem ...

    SBIR Phase II 2023 Department of EnergyARPA-E
  8. Disseminable Evidence-Based Treatment for the Dental Office: Virtual Exposure Tools for Dental Fear- neVR Fear the Dentist

    SBC: VIRTUALLY BETTER INC            Topic: NIDCR

    PROJECT SUMMARY/ABSTRACTEach year over 20 million adults with moderate fear and over 14 million adults with severe fear visit the dentist. Because fear portends poor future oral health, patients with dental fear come to experience their worst fears: pain, surgical procedures, and the need for more frequent dental visits. Avoidance is the natural and reinforced response, ironically guaranteeing a r ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Cutaneous Phosphorylated Alpha-Synuclein for Detection of Prodromal Synucleinopathies

    SBC: CND LIFE SCIENCES, INC.            Topic: 105

    PROJECT SUMMARY A group of devastating diseases, collectively termed synucleinopathies, affect over 2 million people in the U.S., carry significant morbidity, high mortality and enormous associated health care costs. Synucleinopathies are characterized by the abnormal deposition of a misfolded protein, phosphorylated α−synuclein (P-SYN), within the central and peripheral nervous systems. Synucl ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  10. A new approach to monitoring glycosylation during glycoprotein production

    SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC            Topic: 300

    PROJECT SUMMARY During the production of therapeutic biologicals, glycosylation has been identified as a critical quality attribute (CQA) that must be carefully monitored to ensure that the desired protein stability, immunogenicity, antibody effector function, pharmacological safety and potency, and serum half-life are consistently obtained. Many factors can affect the composition of the glycan ch ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government